Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α-synuclein preformed fibrils-induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero-Murillo, Djordje O. Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría
The paper uses proteomic analysis of the olfactory tract to identify pyroxamide, an HDAC1 inhibitor, as a potential therapeutic for Parkinson's disease by reducing α-synuclein fibril-induced toxicity in cell lines.
Brain Pathology · Aug 30, 2026Peer-reviewedNeuroscience